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Abstract 
The multi-subunit eEF1 complex plays a crucial role in de novo protein synthesis. The central 
functional component of the complex is eEF1A, which occurs as two independently encoded 
variants with reciprocal expression patterns: whilst eEF1A1 is widely expressed, eEF1A2 is 
found only in neurons and muscle. Heterozygous mutations in the gene encoding eEF1A2, 
EEF1A2, have recently been shown to cause epilepsy, autism and intellectual disability. The 
remaining subunits of the eEF1 complex, eEF1B, eEF1D, eEF1G and VARS, together form 
the GTP exchange factor for eEF1A and are ubiquitously expressed, in keeping with their 
housekeeping role. However, mutations in the EEF1B2, EEF1D and VARS genes have also 
now been identified as causes of neurodevelopmental disorders. In this review we describe 
the mutations identified so far in comparison with the degree of normal variation in each 
gene, and the predicted consequences of the mutations on the functions of the proteins and 
their isoforms. We discuss the likely effects of the mutations in the context of the role of 
protein synthesis in neuronal development. 
  
Introduction 
There is growing evidence that precise translational homeostasis is necessary within neurons, 
and that imbalances in the equilibrium of protein synthesis can result in aberrant 
neurodevelopment. The use of new genetic sequencing techniques in neurodevelopmental 
disorders (including autism, intellectual disability and epilepsy) has led to the identification 
of many new causative genes, either in families or in individuals with de novo mutations 
identified by sequencing parent-child trios. In recent years, individuals with mutations in 
genes encoding subunits of the translation elongation eEF1 complex have been discovered, 
implicating the elongation stage of translation as a key modulator of healthy neuronal 
development. Here we describe the range of mutations in components of the eEF1 translation 
elongation complex, all of which have been implicated in neurodevelopmental disorders. 
Whilst some of the mutations are seen in ubiquitously expressed factors, others affect 
isoforms of the protein that are preferentially expressed in neurons. Overall, the evidence 
demonstrates the need for tightly controlled expression of protein synthesis factors in 
neurons.  
The eEF1 complex and functions of the subunits 
Translation elongation is modulated by eukaryotic translation elongation factor 1A (eEF1A), 
which delivers aminoacylated tRNAs to the ribosome to lengthen nascent polypeptides. This 
process requires GTP; the rate of intrinsic spontaneous GDP release is low, but GDP release 
is increased 1000 fold in the presence of cognate guanine exchange factor eEF1B (Janssen & 
Möller, 1988).  Together eEF1A and the subunits of eEF1B make the eEF1 complex. The 
complex, its architecture, composition, roles in translation and non-canonical function have 
been extensively reviewed in the past (Le Sourd et al., 2006; Mateyak & Kinzy, 2010; 
Minella, Mulner-Lorillon, Bec, Cormier, & Bellé, 1998; Sasikumar, Perez, & Kinzy, 2012).  
eEF1A 
eEF1A has two protein isoforms in mammals, encoded by separate genes, which are 92% 
identical and 98% similar at the amino acid level (Ann et al., 1991; Lund, Knudsen, Vissing, 
Clark, & Tommerup, 1996). Each isoform appears to function in the canonical role of 
translation elongation with similar protein synthesis kinetics, but with different affinities for 
GTP/GDP, with eEF1A1 favouring GTP and eEF1A2 showing greater affinity for GDP 
(Kahns et al., 1998). Despite this difference, both isoforms have been shown to bind to the 
eEF1B complex (Y. Cao, Portela, Janikiewicz, Doig, & Abbott, 2014; Mansilla et al., 2002). 
eEF1A1 and eEF1A2 have distinct, non-overlapping expression patterns. This accounts for 
the requirement for both proteins, since every cell type will need some form of eEF1A to 
function. eEF1A1 is expressed ubiquitously throughout development but is down-regulated 
postnatally in neurons, cardiomyocytes and myocytes where it is replaced by eEF1A2 
(Khalyfa et al., 2001; S. Lee, Stollar, & Wang, 1993). In view of their similar properties in 
terms of the canonical function of eEF1A in protein synthesis, it has been hypothesised that 
the switch between isoforms occurs because specific cell types have a requirement for 
distinct non-canonical functions not shared by eEF1A1 and eEF1A2 (Abbott et al., 2009). 
One such function is actin binding and bundling, which has been well characterised with 
respect to eEF1A1 (Clore, Dannenhoffer, & Larkins, 1996; Murray, Edmonds, Liu, & 
Condeelis, 1996). The amino acid residues known to interact with actin are found on the face 
of the 3D structure of eEF1A which harbours the majority of amino acid differences  between 
the two isoforms, suggesting that eEF1A1 and eEF1A2 may have different capacities for 
interacting with actin (Soares, Barlow, Newbery, Porteous, & Abbott, 2009). Indeed, there is 
experimental evidence for differences in actin binding and bundling activities between 
eEF1A1 and eEF1A2 (Novosylna et al., 2017). One hypothesis, therefore, is the switch 
occurs so as to modify cytoskeletal interactions in neurons at different developmental stages 
(Abbott et al., 2009). However, it is not possible to rule out the idea that this highly 
conserved switch, seen in all vertebrates, occurs in response to differing needs for some 
aspect of protein synthesis in terminally differentiated, long lived cells.  
eEF1Bα 
eEF1Bα is a cognate guanine exchange factor for eEF1A (Janssen & Möller, 1988; 
Murakami, Ejiri, & Katsumata, 1978) operating in a magnesium dependent manner (Pittman 
et al., 2006). In humans, one protein coding isoform of eEF1Bα has been reported, at around 
32kDa (Bec, Kerjan, Zha, & Waller, 1989), encoded by the EEF1B2 gene. EEF1B1 has been 
shown to be a processed pseudogene, whilst EEF1B3 is a human-specific intronless gene 
transcribed only in brain and muscle (Chambers, Peters, & Abbott, 1998). Although eEF1Bα 
is essential for cell survival in yeast, with knockout strains showing growth defects (Hiraga, 
Suzuki, Tsuchiya, & Miyakawa, 1993), it is dispensible for short term viability, at least, of 
human cells in culture (see below) (Y. Cao et al., 2014). The C-terminal region of the protein 
encompasses the residues necessary for guanine exchange activity (Janssen & Möller, 1988), 
whilst the N-terminal binds to eEF1Bγ, linking eEF1Bα to the rest of the eEF1 complex 
(Mansilla et al., 2002). Indeed the N-terminal binding to eEF1Bγ has been shown to decrease 
catalytic activity of eEF1Bα, as biochemical studies showed a 2.5 increase in GDP exchange 
of eEF1A2 when the N-terminal of eEF1Bα was completely truncated (Trosiuk, Shalak, 
Szczepanowski, Negrutskii, & El’skaya, 2016). 
eEF1Bδ 
eEF1Bδ is also a guanine exchange factor, sharing a high level of sequence homology at the 
C-terminal with eEF1Bα, where both subunits have their guanine exchange domains. 
(Janssen et al., 1991) (Matsumoto, Terui, Xi, Taira, & Ejiri, 1994; Morales, Cormier, Mulner-
Lorillon, Poulhe, & Bellé, 1992). The sequences of the two subunits diverge at the N-terminal 
regions (Sanders, Raggiaschi, Morales, & Möller, 1993), where both, nevertheless, bind to 
eEF1Bγ (Matsumoto et al., 1994) . Three spliceforms encoded by a single gene, EEF1D, each 
giving rise to a protein of predicted size of about 38kDa, have been reported. The same locus 
also encodes a more recently described brain, spinal cord and testis specific isoform called 
eEF1BδL which is expressed throughout brain development in the mouse (Kaitsuka & 
Matsushita, 2015) (Y. Cao et al., 2014). This longer isoform includes an additional 367 
amino acids at the N-terminus, a domain containing a nuclear localisation signal. Kaitsuka 
and colleagues demonstrated that this longer isoform, which is found in both cytoplasm and 
nucleus, functions during cellular stress as a transcription factor for heat shock element-
containing genes. When heatshock is induced, the canonical eEF1Bδ isoform is 
downregulated, and eEF1BδL becomes upregulated. These changes in gene expression thus 
act as a two-pronged stress response system resulting in both downregulation of global 
protein synthesis and the concomitant upregulation of heat shock factors (Kaitsuka, 
Tomizawa, & Matsushita, 2011). It is as yet unclear whether the eEF1BδL longer isoform 
binds to the other subunits of eEF1B in the same way as the canonical isoform, and is thus 
able to act as a guanine exchange factor.  The smaller isoforms of eEF1D are ubiquitously 
expressed in mouse, but are more highly expressed in brain and liver at fetal and neonatal 
stages than from p10 onwards (Y. Cao et al., 2014). In contrast, eEF1BδL is expressed at in 
brain at all developmental stages tested, increasing slightly with age (Y. Cao et al., 2014). 
eEF1Bγ 
eEF1Bγ is encoded by a single gene, EEF1G, that is transcribed ubiquitously. eEF1Bγ 
possesses no innate guanine exchange activity (Kinzy, Ripmaster, & Woolford, 1994) but 
may have the capacity to stimulate GTP exchange via eEF1Bα (Mulner-Lorillon et al., 1994). 
The protein contains a GST-transferase like domain at the N-terminus, a sequence often 
associated with structural proteins. eEF1Bγ has also been co-purified with tubulin (Janssen & 
Möller, 1988), keratin (Kim, Kellner, Lee, & Coulombe, 2007) and the endoplasmic 
reticulum (Sanders, Brandsma, Janssen, Dijk, & Möller, 1996), consistent with a role as an 
anchoring subunit.  
Valyl tRNA synthetase 
Valyl-tRNA synthetase (ValRS) has been shown to form a stable complex with eEF1 (1–3), 
the only tRNA synthetase known to do so in higher eukaryotes. tRNA synthetases catalyse 
the aminoacylation of their corresponding tRNA, a process that is followed by the subsequent 
delivery of the aminoacyl-tRNA (aa-tRNA) to the ribosome by eEF1A. The consecutive 
nature of these steps suggests that the purpose of the interaction between ValRS and eEF1 is 
to enhance the catalytic activity of ValRS (1–6) and to play a role in amino acid channelling. 
This channeling is the process by which there is a direct transfer of the newly synthesized aa-
tRNA to the ribosome via eEF1A, without mixing the intermediate substrates with the total 
fluid of the cell (7). Amino acid channelling, therefore, is thought to contribute to fidelity and 
efficiency, and thus to translational homeostasis, by coupling two stages of translation. 
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Structure and function of the eEF1 complex 
Several models of the eEF1 complex have been proposed, based on different types of 
interaction studies in a variety of organisms (Bec, Kerjan, & Waller, 1994; Janssen, van 
Damme, Kriek, Amons, & Möller, 1994; Jiang, Wolfe, Warrington, & Norcum, 2005; 
Mansilla et al., 2002; Minella et al., 1998; Sheu & Traugh, 1999); these have been reviewed 
previously (Le Sourd et al., 2006; Minella et al., 1998; Sasikumar et al., 2012). There is a 
consensus that eEF1A binds to guanine exchange factors eEF1Bδ and eEF1Bα at the C-
terminus, the site at which where GDP exchange occurs. The latter two bind to eEF1Bγ 
(Janssen et al., 1994; Matsumoto et al., 1994). eEF1Bγ itself possesses no GDP exchange 
activity (Kinzy et al., 1994), but has been shown to bind  to tubulin, and the endoplasmic 
reticulum, suggesting that it can function as a structural anchoring protein (Sanders et al., 
1996). ValRS is bound via its N-terminal to eEF1Bδ.  
Cao et al (Y. Cao et al., 2014) used siRNA to examine the effect of attenuating expression of 
single eEF1B subunits in mammalian cells in culture. Silencing of any one of eEF1Bα, 
eEF1Bδ and eEF1Bγ in several cell lines resulted in small but significant reductions in cell 
viability and subtle shifts in cell cycle distribution but stopped short of resulting in complete 
lethality. No knockout experiments have been carried out for eEF1B subunits in higher 
organisms but it seems likely that long term ablation of any one subunit would affect growth 
and viability. 
Mutations in eEF1 complex subunits cause neurodevelopmental abnormalities 
It is of no surprise that alteration to components of the protein translation machinery would 
have significant effects on cellular metabolism and function, but it is only now, with the 
widespread use of exome sequencing, that mutations in translation elongation factors are 
being associated with specific clinical conditions. Neurodevelopment seems to be particularly 
dependent on optimal functioning of translation factors, presumably due to the requirement 
for local de novo protein synthesis at synapses in the formation of memory. All eEF1 subunits 
have been shown to be enriched in proteomic studies of post-synaptic densities, consistent 
with a role in learning and memory (Bayés et al., 2011). However, a further explanation for 
the association between mutations in translation factors and specific defects in neuronal 
function could come from the presence of mutations in neuronal-specific isoforms of 
otherwise ubiquitously expressed proteins. Below we review the evidence for each 
component of the eEF1 complex.  
EEF1A2 
The subunit of eEF1 most strongly associated with disorders of neurodevelopment is 
eEF1A2. eEF1A2 was first implicated in neurological disorders when a spontaneous 15.8kb 
deletion including the promoter and first exon of the gene was identified in mice displaying a 
severe neurodegenerative phenotype. Mice homozygous for the deletion undergo muscular 
and neuronal degeneration, the onset of which coincides with the down-regulation of eEF1A1 
in these cell types (Khalyfa et al., 2001; Newbery et al., 2007). eEF1A2, unlike eEF1A1, is 
not expressed in tissues other than neurons and muscle, so it is reasonable to assume that 
mutations would be better tolerated than those in ubiquitously expressed eEF1 subunits.  
Analysis of the EEF1A2 gene in human populations shows that it is highly constrained (table 
2). Very few coding changes are seen, and none occur in more than a handful of individuals. 
In contrast, multiple independent heterozygous de novo missense mutations in EEF1A2 have 
been identified in individuals with varying neurodevelopmental phenotypes including 
epilepsy, autism and intellectual disability (table 3). Initially, the mutations described were all 
associated with severe disorders, but more recently mutations in EEF1A2 have been found in 
milder cases of epilepsy (Epi4K consortium & Epilepsy Phenome/Genome Project, 2017). 
A homozygous mutation in EEF1A2 has recently been described for the first time in the 
human population, occurring three times within a single family.  Children homozygous for 
the P333L mutation showed failure to thrive, global developmental delay, severe epilepsy, 
and dilated cardiomyopathy leading to death in early childhood. Both parents were 
heterozygous for the same P333L missense mutation, but had no overt clinical features (the 
father has slight behavioural abnormalities). The P333L mutation is not seen in ExAc and is 
predicted to be pathogenic, but is clearly much milder in a heterozygous form than the 
previously described mutations, consistent with wide ranging allelic heterogeneity for 
mutations in this gene.  
The unusual profile of mutations in EEF1A2 in human, in which all mutations with one 
possible exception are missense, suggests either that heterozygous loss of function is 
incompatible with life, or that the missense mutations confer a gain of function or dominant 
negative effect. In fact, deletions encompassing the EEF1A2 gene have been identified; in 
each case the affected individual has epilepsy and ID/developmental delay, but as the 
deletions also affect neighbouring genes such as KCNQ2, another well-established epilepsy 
gene, it is impossible to ascribe the phenotype to any one deleted gene (Faheem et al., 2015). 
That these individuals survive does, however, suggest that haploinsufficiency for EEF1A2 is 
not lethal and that the missense mutations may result in some form of cellular toxicity.  
EEF1B2 
The EEF1B2 gene encodes the guanine exchange factor subunit eEF1Bα. A homozygous 3 
kb mutation in EEF1B2, predicted to result in the loss of an exon, has been described in three 
siblings, all with moderate intellectual disability (Najmabadi et al., 2011). It initially seems 
unexpected that a mutation in the ubiquitously expressed guanine exchange factor for both 
eEF1A1 and eEF1A2 would give rise to a specific neurological phenotype (in contrast to the 
situation with mutations in EEF1A2, where the gene is expressed specifically in neurons). 
However, EEF1B2 appears not to be essential for cell viability, at least in the short term (Y. 
Cao et al., 2014), and the mutation might not lead to complete loss of function. Furthermore, 
it is possible that there is some degree of functional redundancy between eEF1Bα and 
eEF1Bδ in terms of guanine exchange. The fact that this intellectual disability-causing 
mutation in a ubiquitously expressed gene apparently spares other cell types lends support to 
the idea that neurons are more susceptible to perturbations in protein synthesis.  
EEF1D 
Mutations in the EEF1D gene encoding the second guanine exchange factor eEF1Bδ have 
also been associated with neurodevelopmental abnormalities. A homozygous truncating 
mutation Glu24Serfs*26 has been identified in three cousins with severe intellectual 
disability and microcephaly (Reuter et al., 2017). This mutation is in first exon of the gene, 
which is found only in the neuronal- and testis- specific eEF1BδL isoform described 
previously  (Kaitsuka & Matsushita, 2015). Figure 1 shows the position of the EEF1D 
mutation relative to the alternative isoforms. 
 
Figure 1: Schematic diagram depicting aligned protein coding sequences for the 4 isoforms of 
eEF1D described by Kaitsuka & Matsushita (Kaitsuka & Matsushita, 2015). Triangle marks 
location of eEF1D mutation identified. Mutation shown to only impact the neuronal isoform 
eEF1BδL isoform.  
VARS 
The VARS gene encodes valyl-tRNA synthetase (ValRS). Homozygous missense mutations 
(c.C2653T; p.L885F and c.G3173A; p.R1058Q) have now been found in two independent 
individuals, each presenting with severe ID/DD, microcephaly, seizures and cortical atrophy 
on MRI (Karaca et al., 2015). ValRS, along with other tRNA synthetases, has acquired non-
catalytic domains during evolution. These domains do not appear to influence the canonical 
function of tRNA synthetases but have become evolutionarily conserved, suggesting that 
aminoacyl tRNA synthetase (AARS) genes may have gained additional non-canonical 
functions.  Indeed, some splice forms are reported to be catalytic nulls, highlighting the 
possibility that AARS have developed functions beyond their role in protein synthesis (Lo et 
al., 2014). Lo and colleagues assessed tissue specific expression of these alternative splice 
variants, including that of splice variants encoded by the VARS gene, but brain was not 
included in the analysis. It is possible therefore that alternative splicing of VARS creates a 
neuronal specific isoform which is disproportionately affected in individuals with VARS 
mutations. Alternatively, the neurological phenotype seen in these individuals may again 
reflect a greater dependence of neurons on optimal protein synthesis. 
 
Table 2: ExAc data for genes encoding eEF1 subunits showing extreme constraint for 
EEF1A2 
 








Missense 211.4 29 z = 6.14 
Loss of function 10.1 0 pLI = 0.96 
EEF1B2 
  
Missense 76.4 72 z = 0.25 
Loss of function 8.3 2 pLI = 0.33 
EEF1D 
  
Missense 267.9 282 z = -0.42 
Loss of function 17.8 4 pLI = 0.39 
VARS Missense 518.5 381 z = 2.95 
Loss of function 51.8 11 pLI = 0.68 
 
Data on mutation frequency from ExAc, the aggregation of data from 60K exomes. The Z 
score indicates deviation from expectation, where the higher the value the greater the 
constraint. pLI is the probability of loss of function tolerance; the closer the value to 1, the 
lower the tolerance of the gene to LOF mutations. Lek et al  (Lek et al., 2016) consider a pLI 
value of greater than 0.9 to indicate extreme intolerance, and EEF1A2 is amongst the top few 
percent of most highly constrained genes.  
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2015) 
Why do mutations in genes with housekeeping functions lead to neurological disorders? 
For each of the genes listed above, the phenotype associated with mutations is predominantly 
one of abnormal neurodevelopment. Given the role of eEF1 in translation, it seems at first 
glance surprising that all organ systems are not affected. There are two obvious possible 
explanations; one, each of these genes has a brain-specific isoform that is exclusively affected 
by the known mutations, or two, that neurons are more susceptible to perturbations in 
translation than are other cell types, that. In fact there is good evidence, as discussed below, 
to believe that each of these explanations may be true, depending on circumstance.  
Neuronal- specific isoforms? 
In the case of mutations in EEF1A2, there is a direct connection between site of expression 
and phenotype, as the gene is expressed only in neurons and muscle (both skeletal and 
cardiac). The mutational spectrum so far established, with multiple individual missense 
mutations occurring de novo and very few coding changes found in normal exomes (table 2), 
presents a picture of a gene very intolerant of any mutation. The severity of the 
neurodevelopmental phenotype seen, even in heterozygotes, is consistent with this picture. 
The only known cases of homozygous mutation in humans (in a single family) manifested as 
cardiomyopathy in addition to impaired neurodevelopment and epilepsy, but again this is 
consistent with the tissue-specific expression pattern of EEF1A2. Mice that carry biallelic 
mutations, either G70S missense or null, die before 4 weeks of age of seizures, sudden death, 
and/or neurodegeneration (Davies et al., 2017). Further mouse mutant lines will need to be 
established and analysed in order to establish whether cardiomyopathy is specific to the 
P333L mutation or whether there is a fundamental difference in the way mice and humans 
respond to lost or compromised eEF1A2. Nevertheless, the key point is that the restricted 
expression pattern is consistent with organ systems affected.  
As described above, a brain and testis specific alternative splice form encoded by EEF1D has 
been identified, called eEF1BδL (Kaitsuka et al., 2011). This alternative splice form, which 
contains an additional exon encoding an N terminal extension of the canonical protein, acts as 
a transcriptional activator of heat shock genes. However, the C-terminal region of the protein 
is conserved between the two isoforms, suggesting that both could also function in translation 
elongation. The intellectual disability-causing mutation in the EEF1D gene is found in this 
additional brain- and testis-specific exon, such that any deleterious effects would be expected 
to be confined to these tissues, but it is not yet clear whether the mutations impact on 
translation elongation, heat shock activation, or both.  
Differential effects of mutations on neuronal protein synthesis? 
It is well established that neurons, with their high metabolic requirement, are particularly 
sensitive to perturbations in protein synthesis. The synapse is a dynamic environment that 
needs to be able to respond quickly to stimuli in order to promote synaptic maintenance, 
growth and plasticity (Fernandez-Moya, Bauer, & Kiebler, 2014; Martin & Ephrussi, 2009; 
West & Greenberg, 2011). Furthermore, the compartmentalised structure of neurons, and 
their resulting need for spatiotemporal control over the synthesis of new proteins, is likely to 
make them more vulnerable than other cell types to mutations that affect translational control. 
Localised protein synthesis is essential to allow proteins that would undergo rapid turnover to 
reach the synapse before degradation can occur (Alvarez & Torres, 1985; Piper & Holt, 
2004). Studies of mutations implicated in neurodevelopmental disorders specifically led to 
the “synaptic hypothesis”, that neurodevelopmental disorders result from impaired assembly 
and/or maintenance of synapses (Gigek et al., 2015). Elongation factors have certainly been 
shown to be key in the lasting potentiation of synapses (Giustetto et al., 2003; Roy et al., 
2018). Both isoforms of eEF1A have been reported to be present at synapses and to have a 
role in clustering of gephyrin, a scaffold protein involved in anchoring receptor molecules to 
postsynaptic membranes (Becker, Kuhse, & Kirsch, 2013).  Overall, then, these findings, 
lend weight to the argument that mutations in even widely expressed translation elongation 
factors could lead specifically to synaptic or overall neuronal dysfunction, resulting in 
neurodevelopmental disorders.  
Mutations in other components of the translational machinery have also been implicated in 
neurodevelopmental disorders. Fragile X syndrome, the most common inherited form of 
intellectual disability, results from the loss of function of a translational regulator, FMRP, and 
the failure to repress translation of specific mRNAs in neurons (Darnell & Klann, 2013). 
Mutations in amino-acyl tRNA synthetases other than VARS have been identified in 
numerous neurological disorders including peripheral neuropathy, epilepsy, intellectual 
disability and microcephaly (Coughlin et al., 2015; Kapur & Ackerman, 2018; Kapur, 
Monaghan, & Ackerman, 2017; Kodera et al., 2015; Musante et al., 2017; Nakayama et al., 
2017; Tsai et al., 2017; Zhang et al., 2014). Unlike VARS, these other amino-acyl tRNA 
synthetases are not associated with the eEF1B complex, and there is no evidence that the 
clinical mutations have arisen in neuronal-specific transcripts. There is thus significant 
evidence to support the hypothesis that mutations to key components of the translational 
machinery affect neurons more severely than other cell types. Alternatively, if the role of 
VARS in eEF1 is to support amino acid channeling, as suggested by Negrutskii et al 
(Negrutskii, Shalak, Kerjan, El’skaya, & Mirande, 1999), perhaps the neurodevelopmental 
phenotypes associated with mutations in VARS reflect a greater dependence of developing 
neurons than other cell types on channeling.  
Whilst it is well established that perturbations in protein synthesis can lead to 
neurodegeneration (J. W. Lee et al., 2006), the disorders described in this review all affect 
neurodevelopment, but with differences in severity and phenotype depending on the function 
of the mutated gene, and the nature of the mutation in that gene. Establishing the 
developmental expression pattern of specific genes may shed light on the processes likely to 
be affected by mutations in those genes.  With increasing RNAseq data being generated and 
collated, we can now study expression of genes across developmental timepoints. Resources 
such as BrainCloud and BrainSpan enable researchers to use both top-down and bottom-up 
approaches to identify genes which would likely be involved in neurodevelopmental 
disorders and the neurodevelopmental timepoints most likely to be impacted by the presence 
of mutations in specific genes (Kang et al., 2011; Tebbenkamp, Willsey, State, & Sestan, 
2014). Whilst transcripts encoding eEF1 subunits eEF1A1, eEF1B2, eEF1D and eEF1G are 
expressed throughout brain development, generally declining after birth, eEF1A2 expression 
increases throughout embryonic development, peaking after birth in a pattern consistent with 
that seen for synapse development and maturation. This is consistent with data from mice and 
rats (Chambers et al., 1998; Khalyfa et al., 2001; S. Lee, Wolfraim, & Wang, 1993). It is 
possible, therefore, that mutations in the gene encoding eEF1A2, in contrast to other 
translation factors, may exert a greater effect on synaptogenesis than on neuronal 
proliferation. More detailed functional studies, including developmental timepoint specific 
conditional gene targeting, will shed further light on these issues, and will help us to 
understand not only how protein synthesis perturbation affects neurons, but why different 
neurodevelopmental phenotypes arise from mutations in apparently housekeeping genes.  
Our knowledge of the effects of mutations in elongation factors contributes to the growing 
understanding of the importance of neuronal protein synthesis. Although it is well established 
that the disruption to the initiation phase of translation can have neurodevelopmental 
consequences, it has only relatively recently become clear that mutations in elongation 
factors can also affect neurodevelopment. Whilst the neuronal specific phenotype is readily 
understandable in the cases of both EEF1A2 and EEF1D, it is initially more surprising that 
partial deletion of the EEF1B2 gene should specifically affect neurons. These cases now join 
the large number of neurodevelopmental phenotypes resulting from mutations in 
housekeeping genes, highlighting the requirement of neurons, in comparison to other cell 
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